Search results for "OUTCOME"

showing 10 items of 5148 documents

An assessment of prime‐boost vaccination schedules with AS03A‐adjuvanted prepandemic H5N1 vaccines: a randomized study in European adults

2012

Please cite this paper as: Gillard et al. (2012) An assessment of prime‐boost vaccination schedules with AS03A‐adjuvanted prepandemic H5N1 vaccines: a randomized study in European adults. Influenza and Other Respiratory Viruses DOI: 10.1111/j.1750‐2659.2012.00349.x. Background  Long‐term persistence of immune response and safety of an H5N1 prepandemic influenza vaccine adjuvanted with AS03 (an α‐tocopherol oil‐in‐water emulsion‐based adjuvant system) was evaluated using various prime‐boost schedules that mimicked potential pandemic scenarios (NCT00430521). Methods  Five hundred and twelve healthy adults aged 18–60 years received primary vaccination with one or two doses (0, 21 days schedule…

AdultMaleAdolescentalpha-TocopherolImmunization SecondaryAntibodies ViralAS03Young Adultprime‐boostAdjuvants ImmunologicInfluenza HumanHumansAdjuvantImmunization ScheduleInfluenza A Virus H5N1 SubtypeVaccinationOriginal ArticlesH5N1Hemagglutination Inhibition TestsMiddle AgedAntibodies NeutralizingTreatment OutcomeInfluenza VaccinesOriginal ArticleFemaleinfluenzaprepandemicInfluenza and Other Respiratory Viruses
researchProduct

Hematopoietic peripheral circulating blood stem cells as an independent marker of good transfusion management in patients with β-thalassemia: results…

2015

Beyond hemoglobin (Hb) levels and performance status, further surrogate markers of appropriate transfusion management should improve the quality of thalassemia care. We investigated the levels of peripheral circulating CD34+ stem cells as an independent marker of appropriate hematopoietic balance in patients with thalassemia.Peripheral circulating CD34+ stem cells, colony-forming unitgranulocyte, erythrocyte, macrophage, magakaryocyte (CF-GEMM), colony-forming unitgranulocyte/macrophage (CFU-GM), and erythroidburst-forming units (BFU-E) were assayed, according to standard procedures. Patients with thalassemia major (TM) and thalassemia intermedia (TI) were tested and compared to healthy con…

AdultMaleAdolescentbeta-ThalassemiaHematopoietic Stem Cell TransplantationPilot ProjectsMiddle AgedHematopoietic Stem CellsPrognosisSettore MED/15 - Malattie Del SangueYoung AdultPeripheral CD34+ stem cells beta-thalassemiaTreatment OutcomeCase-Control StudiesHumansFemaleBiomarkersAgedFollow-Up Studies
researchProduct

Analgesic efficacy of ketorolac associated with a tramadol/acetaminophen combination after third molar surgery - a randomized, triple-blind clinical …

2019

Background This study compared the efficacy of ketorolac alone versus its combination with tramadol/acetaminophen for pain control after mandibular third molar surgery. Material and Methods A randomized, triple-blind clinical trial was carried out with 52 patients divided into 2 groups: Group K+T+A (1 tablet of Ketorolac 10 mg plus and 1 capsule of Tramadol 37.5 mg/acetaminophen 325 mg) and Group K (1 tablet of Ketorolac 10 mg plus and 1 placebo capsule). The treatments were given 1 h before the surgery and was repeated 4 times per day, for 48 h. The difference in postoperative pain was assessed by 4 primary end-points: pain intensity (VAS 100mm, for 48 h), rescue medication, overall assess…

AdultMaleAdolescentmedicine.drug_classAnalgesicPlacebolaw.inventionYoung Adult03 medical and health sciences0302 clinical medicineDouble-Blind MethodRandomized controlled triallawHumansMedicineAntiemeticAdverse effectGeneral DentistryTramadolAcetaminophenPain Postoperativebusiness.industryResearchAnti-Inflammatory Agents Non-Steroidal030206 dentistryAnalgesics Non-Narcotic:CIENCIAS MÉDICAS [UNESCO]AcetaminophenAnalgesics OpioidKetorolacTreatment OutcomeOtorhinolaryngologyAnesthesiaUNESCO::CIENCIAS MÉDICASTooth ExtractionDrug Therapy CombinationFemaleMolar ThirdSurgeryTramadolAnalgesiaOral SurgerybusinessKetorolac030217 neurology & neurosurgerymedicine.drugMedicina Oral Patología Oral y Cirugia Bucal
researchProduct

Prediction of the hemoglobin level in hemodialysis patients using machine learning techniques

2013

HighlightsDifferent prediction algorithms were used to predict Hb levels in CRF patients.Prediction errors in the validation cohorts of patients were around 0.6g/dl.Difficulty to obtain lower errors due to the measuring machine precision (0.2g/dl).Relevance analysis of features have been applied for each predictor. Patients who suffer from chronic renal failure (CRF) tend to suffer from an associated anemia as well. Therefore, it is essential to know the hemoglobin (Hb) levels in these patients. The aim of this paper is to predict the hemoglobin (Hb) value using a database of European hemodialysis patients provided by Fresenius Medical Care (FMC) for improving the treatment of this kind of …

AdultMaleAdolescentmedicine.medical_treatmentHealth InformaticsMachine learningcomputer.software_genreDisease clusterSensitivity and SpecificityHemoglobinsYoung AdultArtificial IntelligenceRenal DialysismedicineHumansComputer SimulationCluster analysisErythropoietinAgedAged 80 and overDose-Response Relationship DrugArtificial neural networkbusiness.industryModels CardiovascularLinear modelReproducibility of ResultsAnemiaMiddle AgedRegressionDrug Therapy Computer-AssistedComputer Science ApplicationsSupport vector machineTreatment OutcomeAdaptive resonance theoryFemaleHemodialysisArtificial intelligenceDrug MonitoringbusinesscomputerAlgorithmsBiomarkersSoftwareComputer Methods and Programs in Biomedicine
researchProduct

Virtual reality versus computer-aided exposure treatments for fear of flying

2011

Evidence is growing that two modalities of computer-based exposure therapies—virtual reality and computer-aided psychotherapy—are effective in treating anxiety disorders, including fear of flying. However, they have not yet been directly compared. The aim of this study was to analyze the efficacy of three computer-based exposure treatments for fear of flying: virtual reality exposure therapy (VRET), computer-aided exposure with a therapist’s (CAE-T) assistance throughout exposure sessions, and self-administered computer-aided exposure (CAE-SA). A total of 60 participants with flying phobia were randomly assigned to VRET, CAE-T, or CAE-SA. Results indicate that the three interventions were …

AdultMaleAircraftPsychological interventionImplosive TherapyFlying PhobiaStatistics NonparametricVirtual realitylaw.inventionExposureFear of flyingVirtual Reality Exposure TherapyUser-Computer InterfaceArts and Humanities (miscellaneous)Randomized controlled trialFear of flyinglawDevelopmental and Educational PsychologymedicineHumansComputer SimulationAnalysis of VarianceIntention-to-treat analysisModalitiesfungiPor a volar--Tractament--Simulació per ordinadorFearMiddle Agedmedicine.diseaseFear of flying --Treatment--Computer simulationIntention to Treat AnalysisTreatmentClinical PsychologyTreatment OutcomePhobic DisordersComputer-aidedPatient SatisfactionRandomized controlled trialTherapy Computer-AssistedAnxietyFemalemedicine.symptomPsychologyClinical psychology
researchProduct

Virtual reality treatment of flying phobia.

2002

Flying phobia (FP) might become a very incapacitating and disturbing problem in a person's social, working, and private areas. Psychological interventions based on exposure therapy have proved to be effective, but given the particular nature of this disorder they bear important limitations. Exposure therapy for FP might be excessively costly in terms of time, money, and efforts. Virtual reality (VR) overcomes these difficulties as different significant environments might be created, where the patient can interact with what he or she fears while in a totally safe and protected environment, the therapist's consulting room. This paper intends, on one hand, to show the different scenarios desig…

AdultMaleAircraftmedicine.medical_treatmentApplied psychologyExposure therapyPsychological interventionVirtual realitySensitivity and SpecificityFlying PhobiaUser-Computer InterfaceComputer GraphicsMedicineHumansPatient treatmentComputer SimulationElectrical and Electronic EngineeringSimulationTravelConsulting roomCognitive Behavioral Therapybusiness.industryReproducibility of ResultsGeneral MedicineFearComputer Science ApplicationsMultiple baseline designTreatment OutcomePhobic DisordersTherapy Computer-AssistedChronic DiseaseAerospace MedicinePanic DisorderFemaleUser interfaceDesensitization PsychologicbusinessBiotechnologyIEEE transactions on information technology in biomedicine : a publication of the IEEE Engineering in Medicine and Biology Society
researchProduct

Longterm Risk of Solid Organ De Novo Malignancies After Liver Transplantation: A French National Study on 11,226 Patients

2018

IF 3.756; International audience; De novo malignancies are one of the major late complications and causes of death after liver transplantation (LT). Using extensive data from the French national Agence de la Biomédecine database, the present study aimed to quantify the risk of solid organ de novo malignancies (excluding nonmelanoma skin cancers) after LT. The incidence of de novo malignancies among all LT patients between 1993 and 2012 was compared with that of the French population, standardized on age, sex, and calendar period (standardized incidence ratio; SIR). Among the 11,226 LT patients included in the study, 1200 de novo malignancies were diagnosed (10.7%). The risk of death was app…

AdultMaleAlcoholic liver diseasemedicine.medical_specialtyTime Factorsmedicine.medical_treatmentPopulation[SDV.CAN]Life Sciences [q-bio]/Cancer030230 surgeryLiver transplantationGastroenterologyRisk AssessmentLiver transplantation (LT)End Stage Liver Disease03 medical and health sciences0302 clinical medicinePostoperative ComplicationsRisk FactorsInternal medicineNeoplasmsmedicineHumanseducationLiver Diseases AlcoholicTransplantationeducation.field_of_studyHepatologybusiness.industryIncidence (epidemiology)IncidenceAbsolute risk reductionMiddle Agedmedicine.diseaseConfidence interval3. Good healthLiver TransplantationStandardized mortality ratioTreatment Outcome030211 gastroenterology & hepatologySurgeryFemaleFranceRisk assessmentbusinessFollow-Up Studies
researchProduct

BASALIT trial: double-blind placebo-controlled allergen immunotherapy with rBet v 1-FV in birch-related soya allergy.

2016

Background Conflicting results exist on the effect of allergen immunotherapy (AIT) on pollen-related food allergy. We aimed to investigate the efficacy of one-year AIT with the folding variant (FV) of recombinant (r) Bet v 1 on birch-related soya allergy. Methods Of 138 subjects with Bet v 1 sensitization, 82 were positive at double-blind placebo-controlled food challenge (DBPCFC) with soya. A total of 56 of 82 were randomized in the ratio of 2:1 (active: placebo). Per-protocol population (PPP) had received ≥150 μg of allergen or placebo preparation. Outcome measures: lowest observed adverse effect levels (LOAEL), postinterventional occurrence of objective signs (objS) at any dose level, sI…

AdultMaleAllergen immunotherapymedicine.medical_specialtyAllergyImmunologyPopulationmedicine.disease_causePlaceboGastroenterology030207 dermatology & venereal diseases03 medical and health sciencessymbols.namesake0302 clinical medicineAllergenFood allergyStatistical significanceInternal medicinemedicineImmunology and AllergyHumanseducationFisher's exact testBetulaSkin Testseducation.field_of_studybusiness.industryRhinitis Allergic SeasonalAntigens PlantImmunoglobulin EMiddle Agedmedicine.diseaseTreatment Outcome030228 respiratory systemDesensitization ImmunologicImmunologysymbolsQuality of LifeFemaleSoybeansbusinessFood HypersensitivityAllergy
researchProduct

Evaluation of serum s-IgE/total IgE ratio in predicting clinical response to allergen-specific immunotherapy.

2009

Background: To date, no predictive tests for the clinical response to allergen-specific immunotherapy (ASI) are available. Therefore an in vivo or in vitro test would be of great value. Objective: We sought to evaluate pretreatment parameters used in diagnosing allergic rhinitis and determining serum specific IgE (s-IgE) levels, serum total IgE (t-IgE) levels, and blood eosinophil counts and to identify whether can be used to predict clinical improvement in monosensitized patients with allergic rhinitis with or without asthma treated with immunotherapy. Methods:We analyzed 279 patients who had undergone 4 years of ASI administered either by means of the subcutaneous immunotherapy (76 patien…

AdultMaleAllergySettore MED/09 - Medicina InternaRhinitis Allergic PerennialAdolescentmedicine.medical_treatmentImmunologyspecific IgEImmunoglobulin Eblood eosinophil countsYoung AdultBlood serummedicineImmunology and AllergyHumansreceiver operating characteristic curveAsthmaDesensitization (medicine)Retrospective StudiesSkin Testsserum s-IgE/total IgE ratio; allergen-specific immunotherapyHouse dust miteserum s-IgE/total IgE ratiobiologyserum-specific IgE/serum total IgE ratiobusiness.industryAllergen-specific immunotherapy; blood eosinophil counts; receiver operating characteristic curve; serum-specific IgE/serum total IgE ratio; specific IgE; total IgEArea under the curveImmunotherapyAllergensImmunoglobulin EMiddle Agedmedicine.diseasebiology.organism_classificationPrognosisAllergen-specific immunotherapyBlood Cell Counttotal IgEEosinophilsTreatment OutcomeDesensitization ImmunologicSpirometryImmunologybiology.proteinFemalebusiness
researchProduct

Treatment of epistaxis in hereditary hemorrhagic telangiectasia with tranexamic acid - a double-blind placebo-controlled cross-over phase IIIB study.

2014

Abstract Introduction Epistaxis is the most frequent manifestation in hereditary hemorrhagic telangiectasia, in which no optimal treatment exists. It can lead to severe anemia and reduced quality of life. Positive effects of tranexamic acid, an antifibrinolytic drug, have been reported on epistaxis related to this disorder. We sought to evaluate the efficacy of treating nosebleeds in hereditary hemorrhagic telangiectasia with tranexamic acid. Materials and Methods In a randomized, double-blind, placebo controlled, cross-over phase IIIB study, 1 gram of tranexamic acid or placebo was given orally 3 times daily for 3 months for a total of 6 months. Results 22 patients were included in the int…

AdultMaleAntifibrinolyticTime Factorsmedicine.drug_classMedizinAdministration OralPlaceboDrug Administration ScheduleDouble blindQuality of lifeDouble-Blind MethodGermanymedicineHumansTelangiectasiaAgedDiminutionCross-Over Studiesbusiness.industryHematologyMiddle AgedAntifibrinolytic AgentsClinical trialEpistaxisTreatment OutcomeTranexamic AcidAnesthesiaFemaleTelangiectasia Hereditary Hemorrhagicmedicine.symptombusinessTranexamic acidmedicine.drugThrombosis research
researchProduct